Search
Rokitamycin
go.drugbank.com/drugs/DB13409ExperimentalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsDiisopromine
go.drugbank.com/drugs/DB13476ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesIproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsTienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnTienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen an...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIxabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsTirapazamine
go.drugbank.com/drugs/DB04858InvestigationalTirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hy...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesLanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalLanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome. This drug is a long-acting analo...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsTranilast
go.drugbank.com/drugs/DB07615InvestigationalTranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates